Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
1件: FLT3 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
2 Acute myeloid leukemia 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
3 Acute myeloid leukemia 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
4 Adherens junction 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
5 Adherens junction 💬
1件: FGFR1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
6 Adherens junction 💬
1件: FGFR1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
7 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
8 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
9 Adipocytokine signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
10 Adipocytokine signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
11 Adipocytokine signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
12 Adipocytokine signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
13 Adipocytokine signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
14 African trypanosomiasis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
15 African trypanosomiasis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
16 African trypanosomiasis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
17 African trypanosomiasis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
18 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
19 AGE-RAGE signaling pathway in diabetic complications 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
20 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
21 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
22 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
23 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
24 AGE-RAGE signaling pathway in diabetic complications 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
25 Alanine, aspartate and glutamate metabolism 💬
4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
26 Alanine, aspartate and glutamate metabolism 💬
4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
27 Alanine, aspartate and glutamate metabolism 💬
4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
28 Alcoholic liver disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
29 Alcoholic liver disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
30 Alcoholic liver disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
31 Alcoholic liver disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
32 Aldosterone synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
33 Aldosterone synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
34 Aldosterone synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
35 Allograft rejection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
36 Allograft rejection 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
37 Allograft rejection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
38 Alzheimer disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
39 Alzheimer disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
40 Alzheimer disease 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
41 Alzheimer disease 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
42 Alzheimer disease 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
43 Alzheimer disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
44 Alzheimer disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
45 Alzheimer disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
46 Alzheimer disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
47 Amoebiasis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
48 Amoebiasis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
49 Amoebiasis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
50 Amoebiasis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
51 AMPK signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
52 AMPK signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
53 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
54 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
55 Amyotrophic lateral sclerosis 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
56 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
57 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
58 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
59 Amyotrophic lateral sclerosis 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
60 Amyotrophic lateral sclerosis 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
61 Antigen processing and presentation 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
62 Antigen processing and presentation 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
63 Antigen processing and presentation 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
64 Apelin signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
65 Apelin signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
66 Apoptosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
67 Apoptosis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
68 Apoptosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
69 Asthma 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
70 Asthma 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
71 Asthma 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
72 Autophagy - animal 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
73 Autophagy - animal 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
74 Autophagy - other 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
75 Autophagy - other 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
76 B cell receptor signaling pathway 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
77 beta-Alanine metabolism 💬
3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
78 beta-Alanine metabolism 💬
3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
79 beta-Alanine metabolism 💬
3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
80 Bladder cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
81 Bladder cancer 💬
1件: FGFR3 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
82 Bladder cancer 💬
1件: FGFR3 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
83 Bladder cancer 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
84 Breast cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
85 Breast cancer 💬
2件: FGFR1, FLT4 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
86 Breast cancer 💬
2件: FGFR1, FLT4 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
87 Breast cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
88 Breast cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
89 Butanoate metabolism 💬
4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
90 Butanoate metabolism 💬
4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
91 Butanoate metabolism 💬
4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
92 C-type lectin receptor signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
93 C-type lectin receptor signaling pathway 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
94 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
95 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
96 Calcium signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
97 Calcium signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
98 Calcium signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
99 Calcium signaling pathway 💬
1件: CD38 💬 Daratumumab 💬 Daratumumab 10件: 13, 16, 28, 46, 48, 49, 60, 63, 288, 331 💬
100 Calcium signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
101 Calcium signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
102 Calcium signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
103 Calcium signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
104 Cellular senescence 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
105 Cellular senescence 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
106 Cellular senescence 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
107 Cellular senescence 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
108 Central carbon metabolism in cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
109 Central carbon metabolism in cancer 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
110 Central carbon metabolism in cancer 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
111 Central carbon metabolism in cancer 💬
1件: FLT3 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
112 Central carbon metabolism in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
113 Central carbon metabolism in cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
114 Chagas disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
115 Chagas disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
116 Chagas disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
117 Chagas disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
118 Chemical carcinogenesis - reactive oxygen species 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
119 Chemical carcinogenesis - reactive oxygen species 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
120 Chemical carcinogenesis - receptor activation 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
121 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
122 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
123 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
124 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
125 Chemical carcinogenesis - receptor activation 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
126 Chemokine signaling pathway 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
127 Chemokine signaling pathway 💬
2件: JAK2, JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
128 Choline metabolism in cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
129 Choline metabolism in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
130 Choline metabolism in cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
131 Choline metabolism in cancer 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
132 Choline metabolism in cancer 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
133 Cholinergic synapse 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
134 Cholinergic synapse 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
135 Circadian entrainment 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
136 Circadian entrainment 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
137 Circadian entrainment 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
138 Colorectal cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
139 Colorectal cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
140 Colorectal cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
141 Coronavirus disease - COVID-19 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
142 Coronavirus disease - COVID-19 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
143 Coronavirus disease - COVID-19 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
144 Coronavirus disease - COVID-19 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
145 Coronavirus disease - COVID-19 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
146 Coronavirus disease - COVID-19 💬
2件: JAK1, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
147 Coronavirus disease - COVID-19 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
148 Coronavirus disease - COVID-19 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
149 Cortisol synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
150 Cortisol synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
151 Cortisol synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
152 Cushing syndrome 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
153 Cushing syndrome 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
154 Cushing syndrome 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
155 Cushing syndrome 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
156 Cytokine-cytokine receptor interaction 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 29件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
157 Cytokine-cytokine receptor interaction 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
158 Cytokine-cytokine receptor interaction 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
159 Cytokine-cytokine receptor interaction 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
160 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
161 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
162 Cytosolic DNA-sensing pathway 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
163 Cytosolic DNA-sensing pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
164 Diabetic cardiomyopathy 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
165 Diabetic cardiomyopathy 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
166 Dilated cardiomyopathy 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
167 Dilated cardiomyopathy 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
168 Dilated cardiomyopathy 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
169 Efferocytosis 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
170 Efferocytosis 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
171 Endocytosis 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
172 Endocytosis 💬
3件: FGFR2, FGFR3, PDGFRA 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
173 Endocytosis 💬
3件: FGFR2, FGFR3, PDGFRA 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
174 Endometrial cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
175 Epithelial cell signaling in Helicobacter pylori infection 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
176 Epstein-Barr virus infection 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
177 Epstein-Barr virus infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
178 Epstein-Barr virus infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
179 Epstein-Barr virus infection 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
180 Epstein-Barr virus infection 💬
3件: JAK1, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
181 Epstein-Barr virus infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
182 Epstein-Barr virus infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
183 ErbB signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
184 ErbB signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
185 ErbB signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
186 Estrogen signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
187 Fc epsilon RI signaling pathway 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
188 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
189 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
190 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
191 Fluid shear stress and atherosclerosis 💬
1件: KDR 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
192 Fluid shear stress and atherosclerosis 💬
1件: KDR 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
193 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
194 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
195 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
196 Fluid shear stress and atherosclerosis 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
197 Focal adhesion 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
198 Focal adhesion 💬
5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
199 Focal adhesion 💬
5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
200 Focal adhesion 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
201 Folate biosynthesis 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
202 Folate biosynthesis 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
203 Folate transport and metabolism 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
204 Folate transport and metabolism 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
205 FoxO signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
206 FoxO signaling pathway 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
207 FoxO signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
208 GABAergic synapse 💬
3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
209 GABAergic synapse 💬
3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
210 GABAergic synapse 💬
3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
211 Gap junction 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
212 Gap junction 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
213 Gap junction 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
214 Gap junction 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
215 Gap junction 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
216 Gastric cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
217 Gastric cancer 💬
1件: FGFR2 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
218 Gastric cancer 💬
1件: FGFR2 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
219 Gastric cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
220 Gastric cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
221 Glioma 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
222 Glioma 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
223 Glioma 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
224 Glioma 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
225 Glioma 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
226 GnRH secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
227 GnRH secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
228 GnRH secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
229 GnRH signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
230 Graft-versus-host disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
231 Graft-versus-host disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
232 Graft-versus-host disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
233 Graft-versus-host disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
234 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
235 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
236 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
237 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
238 Hematopoietic cell lineage 💬
1件: CD38 💬 Daratumumab 💬 Daratumumab 10件: 13, 16, 28, 46, 48, 49, 60, 63, 288, 331 💬
239 Hematopoietic cell lineage 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 29件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
240 Hematopoietic cell lineage 💬
1件: FLT3 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
241 Hematopoietic cell lineage 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
242 Hematopoietic cell lineage 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
243 Hematopoietic cell lineage 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
244 Hematopoietic cell lineage 💬
1件: MS4A1 💬 Rituximab 💬 Rituximab 52件: 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 172, 220, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
245 Hematopoietic cell lineage 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
246 Hematopoietic cell lineage 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
247 Hepatitis B 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
248 Hepatitis B 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
249 Hepatitis B 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
250 Hepatitis B 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
251 Hepatitis B 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
252 Hepatitis B 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
253 Hepatitis B 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
254 Hepatitis C 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
255 Hepatitis C 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
256 Hepatitis C 💬
2件: JAK1, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
257 Hepatitis C 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
258 Hepatitis C 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
259 Hepatitis C 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
260 Hepatocellular carcinoma 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
261 Hepatocellular carcinoma 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
262 Hepatocellular carcinoma 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
263 Herpes simplex virus 1 infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
264 Herpes simplex virus 1 infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
265 Herpes simplex virus 1 infection 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
266 Herpes simplex virus 1 infection 💬
3件: JAK1, JAK2, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
267 Herpes simplex virus 1 infection 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
268 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
269 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
270 Herpes simplex virus 1 infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
271 Herpes simplex virus 1 infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
272 HIF-1 signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
273 HIF-1 signaling pathway 💬
1件: FLT1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
274 HIF-1 signaling pathway 💬
1件: FLT1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
275 HIF-1 signaling pathway 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
276 HIF-1 signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
277 HIF-1 signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
278 HIF-1 signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
279 HIF-1 signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
280 HIF-1 signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
281 Hormone signaling 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
282 Hormone signaling 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
283 Human cytomegalovirus infection 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
284 Human cytomegalovirus infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
285 Human cytomegalovirus infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
286 Human cytomegalovirus infection 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
287 Human cytomegalovirus infection 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
288 Human cytomegalovirus infection 💬
1件: JAK1 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
289 Human cytomegalovirus infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
290 Human cytomegalovirus infection 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
291 Human cytomegalovirus infection 💬
1件: PDGFRA 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
292 Human cytomegalovirus infection 💬
1件: PDGFRA 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
293 Human cytomegalovirus infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
294 Human cytomegalovirus infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
295 Human cytomegalovirus infection 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
296 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
297 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
298 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
299 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
300 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
301 Human papillomavirus infection 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
302 Human papillomavirus infection 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
303 Human papillomavirus infection 💬
2件: JAK1, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
304 Human papillomavirus infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
305 Human papillomavirus infection 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
306 Human papillomavirus infection 💬
1件: PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
307 Human papillomavirus infection 💬
1件: PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
308 Human papillomavirus infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
309 Human papillomavirus infection 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
310 Human papillomavirus infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
311 Human papillomavirus infection 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
312 Human T-cell leukemia virus 1 infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
313 Human T-cell leukemia virus 1 infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
314 Human T-cell leukemia virus 1 infection 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
315 Human T-cell leukemia virus 1 infection 💬
2件: JAK1, JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
316 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
317 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
318 Huntington disease 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
319 Huntington disease 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
320 Huntington disease 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
321 Huntington disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
322 Huntington disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
323 Hypertrophic cardiomyopathy 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
324 Hypertrophic cardiomyopathy 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
325 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
326 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
327 IL-17 signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
328 IL-17 signaling pathway 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
329 IL-17 signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
330 IL-17 signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
331 Inflammatory bowel disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
332 Inflammatory bowel disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
333 Inflammatory bowel disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
334 Inflammatory bowel disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
335 Influenza A 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
336 Influenza A 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
337 Influenza A 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
338 Influenza A 💬
3件: JAK1, JAK2, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
339 Influenza A 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
340 Influenza A 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
341 Influenza A 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
342 Insulin resistance 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
343 Insulin resistance 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
344 Insulin resistance 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
345 Insulin resistance 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
346 Insulin resistance 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
347 Insulin resistance 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
348 Insulin signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
349 Insulin signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
350 Intestinal immune network for IgA production 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
351 Intestinal immune network for IgA production 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
352 JAK-STAT signaling pathway 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 29件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
353 JAK-STAT signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
354 JAK-STAT signaling pathway 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
355 JAK-STAT signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
356 JAK-STAT signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
357 JAK-STAT signaling pathway 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
358 JAK-STAT signaling pathway 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
359 JAK-STAT signaling pathway 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
360 JAK-STAT signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
361 JAK-STAT signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
362 JAK-STAT signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
363 JAK-STAT signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
364 Kaposi sarcoma-associated herpesvirus infection 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
365 Kaposi sarcoma-associated herpesvirus infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
366 Kaposi sarcoma-associated herpesvirus infection 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
367 Kaposi sarcoma-associated herpesvirus infection 💬
3件: JAK1, JAK2, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
368 Kaposi sarcoma-associated herpesvirus infection 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
369 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
370 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
371 Kaposi sarcoma-associated herpesvirus infection 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
372 Legionellosis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
373 Legionellosis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
374 Legionellosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
375 Legionellosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
376 Leishmaniasis 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
377 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
378 Leishmaniasis 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
379 Leishmaniasis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
380 Leishmaniasis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
381 Leishmaniasis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
382 Lipid and atherosclerosis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
383 Lipid and atherosclerosis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
384 Lipid and atherosclerosis 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
385 Lipid and atherosclerosis 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
386 Lipid and atherosclerosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
387 Lipid and atherosclerosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
388 Longevity regulating pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
389 Longevity regulating pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
390 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
391 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
392 Malaria 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
393 Malaria 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
394 Malaria 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
395 Malaria 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
396 MAPK signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
397 MAPK signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
398 MAPK signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
399 MAPK signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
400 MAPK signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
401 MAPK signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
402 MAPK signaling pathway 💬
1件: FLT3 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
403 MAPK signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
404 MAPK signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
405 MAPK signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
406 MAPK signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
407 Measles 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
408 Measles 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
409 Measles 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
410 Measles 💬
3件: JAK1, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
411 Melanoma 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
412 Melanoma 💬
3件: FGFR1, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
413 Melanoma 💬
3件: FGFR1, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
414 MicroRNAs in cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
415 MicroRNAs in cancer 💬
3件: FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
416 MicroRNAs in cancer 💬
3件: FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
417 MicroRNAs in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
418 MicroRNAs in cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
419 MicroRNAs in cancer 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
420 Motor proteins 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
421 Motor proteins 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
422 mTOR signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
423 mTOR signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
424 mTOR signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
425 mTOR signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
426 mTOR signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
427 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
428 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
429 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
430 Necroptosis 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
431 Necroptosis 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
432 Necroptosis 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
433 Necroptosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
434 Necroptosis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
435 Necroptosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
436 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Dexamethasone 💬 Dexamethasone 25件: 13, 14, 16, 19, 28, 35, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 296, 299, 331 💬
437 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Dexamethasone sodium phosphate 💬 Dexamethasone 25件: 13, 14, 16, 19, 28, 35, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 296, 299, 331 💬
438 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Dexamethasone phosphate 💬 Dexamethasone 25件: 13, 14, 16, 19, 28, 35, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 296, 299, 331 💬
439 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisone 💬 Prednisone 54件:  2 , 11, 13, 14, 18, 19, 26, 28, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 60, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 90, 93, 95, 96, 97, 113, 145, 162, 164, 205, 222, 224, 228, 251, 269, 283, 285, 288, 299, 300, 303, 307, 331 💬
440 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
441 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
442 NF-kappa B signaling pathway 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
443 NF-kappa B signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
444 NF-kappa B signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
445 NF-kappa B signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
446 Nicotinate and nicotinamide metabolism 💬
1件: CD38 💬 Daratumumab 💬 Daratumumab 10件: 13, 16, 28, 46, 48, 49, 60, 63, 288, 331 💬
447 NOD-like receptor signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
448 NOD-like receptor signaling pathway 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
449 NOD-like receptor signaling pathway 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
450 NOD-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
451 NOD-like receptor signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
452 NOD-like receptor signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
453 Non-alcoholic fatty liver disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
454 Non-alcoholic fatty liver disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
455 Non-alcoholic fatty liver disease 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
456 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
457 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
458 Non-small cell lung cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
459 Non-small cell lung cancer 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
460 One carbon pool by folate 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
461 One carbon pool by folate 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
462 Osteoclast differentiation 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
463 Osteoclast differentiation 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
464 Osteoclast differentiation 💬
2件: JAK1, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
465 Osteoclast differentiation 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
466 Osteoclast differentiation 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
467 Osteoclast differentiation 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
468 Oxytocin signaling pathway 💬
1件: CD38 💬 Daratumumab 💬 Daratumumab 10件: 13, 16, 28, 46, 48, 49, 60, 63, 288, 331 💬
469 Oxytocin signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
470 Pancreatic cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
471 Pancreatic cancer 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
472 Pancreatic cancer 💬
1件: JAK1 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
473 Pancreatic cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
474 Pancreatic cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
475 Pancreatic cancer 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
476 Pancreatic secretion 💬
1件: CD38 💬 Daratumumab 💬 Daratumumab 10件: 13, 16, 28, 46, 48, 49, 60, 63, 288, 331 💬
477 Parathyroid hormone synthesis, secretion and action 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
478 Parathyroid hormone synthesis, secretion and action 💬
1件: FGFR1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
479 Parathyroid hormone synthesis, secretion and action 💬
1件: FGFR1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
480 Parkinson disease 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
481 Parkinson disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
482 Parkinson disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
483 Pathogenic Escherichia coli infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
484 Pathogenic Escherichia coli infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
485 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
486 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
487 Pathogenic Escherichia coli infection 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
488 Pathogenic Escherichia coli infection 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
489 Pathways in cancer 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 29件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
490 Pathways in cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
491 Pathways in cancer 💬
6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
492 Pathways in cancer 💬
6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
493 Pathways in cancer 💬
2件: FLT3, JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
494 Pathways in cancer 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
495 Pathways in cancer 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
496 Pathways in cancer 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
497 Pathways in cancer 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
498 Pathways in cancer 💬
3件: JAK1, JAK2, JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
499 Pathways in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
500 Pathways in cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
501 Pathways in cancer 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
502 Pathways of neurodegeneration - multiple diseases 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
503 Pathways of neurodegeneration - multiple diseases 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
504 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
505 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
506 Pathways of neurodegeneration - multiple diseases 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
507 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
508 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
509 Pathways of neurodegeneration - multiple diseases 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
510 Pathways of neurodegeneration - multiple diseases 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
511 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
512 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
513 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
514 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
515 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
516 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
517 Pertussis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
518 Pertussis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
519 Pertussis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
520 Pertussis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
521 Phagosome 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
522 Phagosome 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
523 Phospholipase D signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
524 Phospholipase D signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
525 Phospholipase D signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
526 Phospholipase D signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
527 Phospholipase D signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
528 PI3K-Akt signaling pathway 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 29件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
529 PI3K-Akt signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
530 PI3K-Akt signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
531 PI3K-Akt signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
532 PI3K-Akt signaling pathway 💬
2件: FLT3, JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
533 PI3K-Akt signaling pathway 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
534 PI3K-Akt signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
535 PI3K-Akt signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
536 PI3K-Akt signaling pathway 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
537 PI3K-Akt signaling pathway 💬
3件: JAK1, JAK2, JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
538 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
539 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
540 PI3K-Akt signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
541 Platelet activation 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
542 Primary immunodeficiency 💬
1件: BTK 💬 Zanubrutinib 💬 Zanubrutinib 6件: 13, 61, 63, 222, 300, 331 💬
543 Primary immunodeficiency 💬
1件: JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
544 Prion disease 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
545 Prion disease 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
546 Prion disease 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
547 Prion disease 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
548 Prion disease 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
549 Prion disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
550 Prion disease 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
551 Prolactin signaling pathway 💬
1件: JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
552 Prolactin signaling pathway 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
553 Propanoate metabolism 💬
1件: ABAT 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
554 Propanoate metabolism 💬
1件: ABAT 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
555 Propanoate metabolism 💬
1件: ABAT 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
556 Prostate cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
557 Prostate cancer 💬
4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
558 Prostate cancer 💬
4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
559 Prostate cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
560 Prostate cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
561 Proteasome 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
562 Proteoglycans in cancer 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
563 Proteoglycans in cancer 💬
2件: FGFR1, KDR 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
564 Proteoglycans in cancer 💬
2件: FGFR1, KDR 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
565 Proteoglycans in cancer 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
566 Proteoglycans in cancer 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
567 Proteoglycans in cancer 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
568 Proteoglycans in cancer 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
569 Proteoglycans in cancer 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
570 Proteoglycans in cancer 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
571 Rap1 signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
572 Rap1 signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
573 Rap1 signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
574 Rap1 signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
575 Ras signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
576 Ras signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
577 Ras signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
578 Ras signaling pathway 💬
1件: FLT3 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
579 Ras signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
580 Regulation of actin cytoskeleton 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
581 Regulation of actin cytoskeleton 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
582 Regulation of actin cytoskeleton 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
583 Relaxin signaling pathway 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
584 Relaxin signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
585 Renal cell carcinoma 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
586 Rheumatoid arthritis 💬
1件: FLT1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
587 Rheumatoid arthritis 💬
1件: FLT1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
588 Rheumatoid arthritis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
589 Rheumatoid arthritis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
590 Rheumatoid arthritis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
591 Rheumatoid arthritis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
592 Rheumatoid arthritis 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
593 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
594 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
595 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
596 Salivary secretion 💬
1件: CD38 💬 Daratumumab 💬 Daratumumab 10件: 13, 16, 28, 46, 48, 49, 60, 63, 288, 331 💬
597 Salmonella infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
598 Salmonella infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
599 Salmonella infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
600 Salmonella infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
601 Salmonella infection 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine 💬 Vincristine 3件: 26, 34, 331 💬
602 Salmonella infection 💬
9件: TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬 Vincristine sulfate 💬 Vincristine 3件: 26, 34, 331 💬
603 Shigellosis 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
604 Shigellosis 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
605 Shigellosis 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
606 Shigellosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
607 Shigellosis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
608 Shigellosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
609 Signaling pathways regulating pluripotency of stem cells 💬
3件: FGFR1, FGFR2, FGFR3 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
610 Signaling pathways regulating pluripotency of stem cells 💬
3件: FGFR1, FGFR2, FGFR3 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
611 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
612 Signaling pathways regulating pluripotency of stem cells 💬
3件: JAK1, JAK2, JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
613 Signaling pathways regulating pluripotency of stem cells 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
614 Sphingolipid signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
615 Sphingolipid signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
616 Sphingolipid signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
617 Spinocerebellar ataxia 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
618 Spinocerebellar ataxia 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
619 Spinocerebellar ataxia 💬
1件: PSMB5 💬 Bortezomib 💬 Bortezomib 18件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 172, 222, 228, 256, 283, 288, 331 💬
620 Systemic lupus erythematosus 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
621 Systemic lupus erythematosus 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
622 Systemic lupus erythematosus 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
623 T cell receptor signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
624 T cell receptor signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
625 T cell receptor signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
626 Taurine and hypotaurine metabolism 💬
2件: E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
627 Taurine and hypotaurine metabolism 💬
2件: E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
628 Taurine and hypotaurine metabolism 💬
2件: E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
629 TGF-beta signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
630 TGF-beta signaling pathway 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
631 TGF-beta signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
632 Th1 and Th2 cell differentiation 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
633 Th1 and Th2 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
634 Th1 and Th2 cell differentiation 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
635 Th17 cell differentiation 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
636 Th17 cell differentiation 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
637 Th17 cell differentiation 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
638 Th17 cell differentiation 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
639 Th17 cell differentiation 💬
4件: JAK1, JAK2, JAK3, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
640 Th17 cell differentiation 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
641 Th17 cell differentiation 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
642 Th17 cell differentiation 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
643 Thermogenesis 💬
1件: FGFR1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
644 Thermogenesis 💬
1件: FGFR1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
645 Thermogenesis 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
646 Thermogenesis 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
647 Thyroid hormone signaling pathway 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
648 Thyroid hormone signaling pathway 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
649 TNF signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
650 TNF signaling pathway 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
651 TNF signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
652 TNF signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
653 Toll-like receptor signaling pathway 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
654 Toll-like receptor signaling pathway 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
655 Toll-like receptor signaling pathway 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
656 Toll-like receptor signaling pathway 💬
2件: JAK1, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
657 Toll-like receptor signaling pathway 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
658 Toll-like receptor signaling pathway 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
659 Toxoplasmosis 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
660 Toxoplasmosis 💬
3件: JAK1, JAK2, TYK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
661 Toxoplasmosis 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
662 Toxoplasmosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
663 Toxoplasmosis 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
664 Toxoplasmosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
665 Transcriptional misregulation in cancer 💬
1件: FLT1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
666 Transcriptional misregulation in cancer 💬
1件: FLT1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
667 Transcriptional misregulation in cancer 💬
1件: FLT3 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
668 Transcriptional misregulation in cancer 💬
1件: IL6 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
669 Transcriptional misregulation in cancer 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
670 Tuberculosis 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
671 Tuberculosis 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
672 Tuberculosis 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
673 Tuberculosis 💬
2件: JAK1, JAK2 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
674 Tuberculosis 💬
1件: JAK2 💬 Pacritinib 💬 Pacritinib 1件: 331 💬
675 Tuberculosis 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
676 Tuberculosis 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
677 Type I diabetes mellitus 💬
2件: E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
678 Type I diabetes mellitus 💬
2件: E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
679 Type I diabetes mellitus 💬
2件: E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
680 Type I diabetes mellitus 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
681 Type I diabetes mellitus 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
682 Type I diabetes mellitus 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
683 Type II diabetes mellitus 💬
1件: CACNA1G 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
684 Type II diabetes mellitus 💬
1件: CACNA1G 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
685 Type II diabetes mellitus 💬
1件: CACNA1G 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
686 Type II diabetes mellitus 💬
1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
687 Type II diabetes mellitus 💬
1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
688 Type II diabetes mellitus 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
689 Type II diabetes mellitus 💬
1件: TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
690 Type II diabetes mellitus 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
691 Valine, leucine and isoleucine degradation 💬
1件: ABAT 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
692 Valine, leucine and isoleucine degradation 💬
1件: ABAT 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
693 Valine, leucine and isoleucine degradation 💬
1件: ABAT 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
694 VEGF signaling pathway 💬
1件: KDR 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
695 VEGF signaling pathway 💬
1件: KDR 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
696 VEGF signaling pathway 💬
1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
697 Viral carcinogenesis 💬
1件: JAK1 💬 Filgotinib 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
698 Viral carcinogenesis 💬
2件: JAK1, JAK3 💬 Filgotinib maleate 💬 Filgotinib 10件: 46, 53, 56, 96, 97, 107, 222, 271, 300, 331 💬
699 Viral protein interaction with cytokine and cytokine receptor 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
700 Viral protein interaction with cytokine and cytokine receptor 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
701 Viral protein interaction with cytokine and cytokine receptor 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
702 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
703 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬
704 Virion - Hepatitis viruses 💬
1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
705 Yersinia infection 💬
1件: IL6 💬 Siltuximab 💬 Siltuximab 2件: 28, 331 💬
706 Yersinia infection 💬
2件: IL6, TNF 💬 Pomalidomide 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
707 Yersinia infection 💬
1件: TNF 💬 Lenalidomide 💬 Lenalidomide 8件: 16, 26, 28, 34, 49, 284, 300, 331 💬
708 Yersinia infection 💬
1件: TNF 💬 Thalidomide 💬 Thalidomide 21件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 117, 227, 271, 280, 298, 300, 331 💬